NCT04853017: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor

NCT04853017
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have a KRAS/NRAS mutated (G12D or G12R) solid tumor
Exclusions: Patients with known brain metastases; Patients with prior use of immunosuppressive drugs
https://ClinicalTrials.gov/show/NCT04853017

Comments are closed.

Up ↑